Autres langues Simcere Pharmaceutical Group Limited

Actions

2096

HK0000658531

Produits pharmaceutiques

Temps Différé Hong Kong S.E. 07:06:35 31/08/2026			Varia. 5j.	Varia. 1 janv.
11,06 ^HKD	-2,12%		-4,66%	-7,60%

21/08	Le bénéfice attribuable de Simcere Pharmaceutical Group progresse de 38 % au S1	MT
20/08	Simcere Pharmaceutical Group Limited publie ses résultats pour le semestre clos le 30 juin 2026	CI

Autres langues

21/08	Simcere Pharmaceutical Group's H1 Attributable Profit Rises 38%
20/08	Simcere Pharmaceutical Group Limited Reports Earnings Results for the Half Year Ended June 30, 2026
20/08	Simcere Pharmaceutical Group Limited Announces Management Changes, Effective August 20, 2026
30/07	Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2026
09/07	Simcere Pharma's Acute Ischemic Stroke Included in National Essential Medicines List
15/06	Simcere Pharma Gets China Nod for Tumor Drug Trial
12/06	Simcere Pharmaceutical Group Limited Receives Clinical Trial Approval for Sim0689 Pd-1/Vegf Bispecific Antibody
12/06	Simcere Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2025, Payable on or Before July 13, 2026
12/06	Simcere Pharmaceutical Group Limited Enters into A Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
12/06	Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
02/06	Simcere Pharma Wins Promotion Rights for PrimeGenX's Atopic Dermatitis Drug
01/06	Simcere Pharmaceutical Group Limited Enters into Exclusive Promotion Service Agreement with PrimeGenX Therapeutics Co., Ltd
21/05	Simcere Pharmaceutical Group Limited Proposes to Declare A Final Dividend for the Year Ended December 31, 2025
06/05	Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0613 LRRC15 Antibody Drug Conjugate
06/05	Simcere pharmaceutical receives NMPA China clinical trial approval for SIM0613
06/05	Simcere Pharmaceutical Receives Chinese Regulatory Approval to Begin Trials of Tumor Drug
04/05	Wuxi Biocity Biopharmaceutics Co., Ltd. announced that it has received funding from Simcere Pharmaceutical Group Limited, First Light Capital
30/04	Simcere pharmaceutical says NDA for rademikibart accepted by NMPA
30/04	Simcere Pharmaceutical Group Limited Announces Acceptance of New Drug Application for Rademikibart
30/04	Simcere Pharmaceutical's Application for Atopic Dermatitis Drug Accepted in China
29/04	Simcere Pharmaceutical's Profit Jumps 86% in 2025
23/04	Connect Biopharma Holdings Limited Continues Enrollment in Phase 2 Seabreeze Stat Studies for Rademikibart
22/04	Simcere Pharma withdraws NDA for rademikibart, expects to resubmit within April 2026
22/04	Simcere Pharmaceutical Group Limited and Connect Biopharma Hong Kong Limited Jointly Develop Rademikibart
30/03	Connect Biopharma's eczema drug shows promise in China late-stage trial